L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience - PubMed (original) (raw)

Review

. 2008 Mar:18 Suppl 1:25-9.

doi: 10.1007/s10286-007-1005-z. Epub 2008 Mar 27.

Affiliations

Review

L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience

Christopher J Mathias. Clin Auton Res. 2008 Mar.

Abstract

Neurogenic orthostatic hypotension is a cardinal feature of generalised autonomic failure and commonly is the presenting sign in patients with primary autonomic failure. Orthostatic hypotension can result in considerable morbidity and even mortality and is a major management problem in disorders such as pure autonomic failure, multiple system atrophy and also in Parkinson's disease. Treatment is ideally two pronged, using non-pharmacological and pharmacological measures. Drug treatment ideally is aimed at restoring adequate amounts of the neurotransmitter noradrenaline. This often is not achievable because of damage to sympathetic nerve terminals, to autonomic ganglia or to central autonomic networks. An alternative is the use of sympathomimetics (that mimic the effects of noradrenaline, but are not identical to noradrenaline), in addition to other agents that target physiological mechanisms that contribute to blood pressure control.L-threo-dihydroxyphenyslerine (Droxidopa) is a pro-drug which has a structure similar to noradrenaline, but with a carboxyl group. It has no pressor effects in this form. It can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline. Experience in Caucasians and in Europe is limited mainly to patients with dopamine beta hydroxylase deficiency. This review focuses on two studies performed in Europe, and provides information on its efficacy, tolerability and safety in patients with pure autonomic failure, multiple system atrophy and Parkinson's disease. It also addresses the issue of whether addition of dopa decarboxylase inhibitors, when combined with l-dopa in the treatment of the motor deficit in Parkinson's disease, impairs the pressor efficacy of Droxidopa.

PubMed Disclaimer

Similar articles

Cited by

References

    1. No To Shinkei. 1998 Feb;50(2):157-63 - PubMed
    1. Eur J Clin Pharmacol. 1982;23(5):463-8 - PubMed
    1. J Neurol. 1999 Oct;246(10):893-8 - PubMed
    1. Q J Med. 1990 Jun;75(278):617-33 - PubMed
    1. Clin Auton Res. 2006 Apr;16(2):113-20 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources